Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SAGE | Common Stock | Options Exercise | $5.24K | +11.6K | +9.54% | $0.45* | 134K | Feb 10, 2023 | Direct | |
transaction | SAGE | Common Stock | Sale | -$347K | -7.81K | -5.84% | $44.47 | 126K | Feb 10, 2023 | Direct | F1, F2 |
transaction | SAGE | Common Stock | Sale | -$172K | -3.84K | -3.05% | $44.90 | 122K | Feb 10, 2023 | Direct | F1, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SAGE | Stock Options (Right to buy) | Options Exercise | $0 | -11.6K | -100% | $0.00* | 0 | Feb 10, 2023 | Common Stock | 11.6K | $0.45 | Direct | F4 |
Id | Content |
---|---|
F1 | The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
F2 | This transaction was executed in multiple trades at prices ranging from $43.81 USD to $44.77 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
F3 | This transaction was executed in multiple trades at prices ranging from $44.815 USD to $45.03 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
F4 | The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on August 12, 2017. |